Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
34 /100
MEDIUM RISK
Score updated Jul 28, 2026

UPB — Upstream Bio, Inc. Dilution Risk Tracker

Track UPB dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track UPB — Get alerts when the score changes →

As of July 28, 2026, Upstream Bio, Inc. (UPB) has a DilutionWatch DilutionScore of 34/100, rated MEDIUM dilution risk. Upstream Bio, Inc. has a market capitalization of $454.95M, 54.42M shares outstanding, 144 institutional holders tracked. Key dilution vectors include approximately 26 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
10
📊 Float Risk
40
⚠️ Warrant Exposure
40
🔄Convertible Debt

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
20%
🔁 Convertible Conversion 40%
• Significant convertible debt: 22% potential dilution
• Elevated convertible risk (60/100)
🔔 Track UPB — Get forecast alerts →

Market Data

Market Cap$454.95M
Shares Outstanding54.42M
Float34.97M
Cash$294.58M
Debt$1.11M
Short InterestN/A

Institutional Holdings

QoQ: ↓ 3.9% shares (2026Q1 vs prior)
144 institutional holders · 49.40M shares
#1 FMR LLC 8.10M shares
#2 ORBIMED ADVISORS LLC 5.69M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 3.75M shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest3.62M
Days to Cover8.2
% of Float10.3%
FINRA data as of Jul 15, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2024-09-30
Full SEC filing analysis available with free account

Recent News

No recent news

What This Means for UPB Shareholders

Upstream Bio, Inc. (UPB) has a DilutionScore of 34/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for UPB shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for UPB in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for UPB alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding UPB's Dilution Risk Factors

Primary Risk Drivers

The two most significant dilution risks for Upstream Bio, Inc. are Convertible Note Risk and Offering Ability. Convertible Note Risk scores at a moderate level, indicating potential exposure to future equity issuance if notes convert into shares. Offering Ability is also elevated, signaling that the company has active programs or plans that could lead to new share issuance. Both factors create pathways for dilution by increasing the total number of shares outstanding, which reduces ownership percentage for existing shareholders.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently at low levels, suggesting minimal near-term dilution pressure from these sources. However, any significant increase in public float or issuance of new warrants could elevate these scores. A change in the company’s capital structure or a major financing event would be key indicators that these factors have shifted into higher risk territory.

SEC Filings to Watch

Investors should monitor several filing types for signs of increased dilution risk. An S-3 registration statement signals potential large-scale offerings, while a 424B5 filing often indicates the launch of new equity programs. An 8-K Item 1.01 filing may reveal material events like new financings or share issuances. Additionally, quarterly reports (10-Q) can highlight changes in capital structure or convertible debt activity that could affect shareholder ownership.

How Dilution Happens

When a company has elevated Convertible Note Risk, it means that existing convertible notes may convert into equity at some point. If the conversion occurs, those notes are exchanged for new shares, increasing the total share count. Offering Ability also plays a role by indicating that the firm is actively preparing to issue more stock, either through rights offerings or public sales. Each of these mechanisms directly increases the number of shares in circulation, reducing each existing shareholder’s proportional ownership.

What Would Make This Worse

A worsening risk profile could occur if the company enters into a convertible note agreement with high conversion triggers or if it files an S-3 offering that includes substantial equity issuance. Additionally, if new warrants are issued without adequate oversight or if the company begins using stock as currency for acquisitions, these actions would significantly increase dilution exposure. A combination of multiple high-risk factors coming online at once could rapidly shift the overall dilution risk to a much more concerning level.

Key Insight

While UPB’s current cash runway is strong, its moderate dilution exposure from convertible notes and offering ability requires careful monitoring of upcoming filings and capital structure changes.

How to Monitor UPB for Dilution Risk

What This Risk Level Means

For a small-cap operating company like Upstream Bio, Inc. (UPB), a medium dilution risk score reflects a moderate potential for share dilution through equity issuance mechanisms. In the context of small-cap companies, where capital is often scarce and funding rounds are frequent, this level of risk suggests that while the company is not immediately threatened by dilution, it has structural elements that could increase exposure if certain conditions arise. Companies in this category typically engage in financing activities such as offerings or convertible notes to fund operations or growth initiatives.

What Typically Happens Next

Small-cap operating companies with moderate dilution risk often proceed through capital-raising activities such as shelf registrations, ATM programs, or warrant exercises. These mechanisms are commonly used to raise capital without the need for a full IPO or traditional financing round. Convertible notes and warrants are especially prevalent among growth-stage companies like UPB, where investors are offered equity at a discount. Monitoring these instruments is essential, as they can significantly impact share count and dilution levels if exercised or converted.

Monitoring Playbook

To track UPB’s dilution risk using DilutionWatch, set up alerts for any changes in Offering Ability, Float Risk, Warrant Exposure, or Convertible Note Risk scores. Check these metrics weekly and monitor SEC filings closely for any new equity issuances or financing events. If a score exceeds 50/100, it's critical to investigate the underlying cause and assess whether the company has initiated a new offering or warrant exercise. Use the Shelf & ATM Monitor to track any public filings related to shelf registrations or ATM programs.

Early Warning Signals

Three key warning signs include: 1) A sudden spike in Convertible Note Risk score, indicating increased issuance or conversion activity; 2) An increase in Warrant Exposure, suggesting new warrant issuances or upcoming exercises; and 3) Changes in Offering Ability, which may indicate a pending capital raise. These signals are especially critical when they occur together, as they often point to an impending dilution event.

What a Positive Resolution Looks Like

A positive shift in UPB’s dilution profile could come from a completed capital raise that reduces the need for future equity issuance, or from warrant expirations that eliminate potential dilution. Additionally, if convertible notes are converted into equity at a later date, this may be offset by improved financial health or operational milestones that reduce reliance on further financing. Any reduction in Offering Ability or Float Risk scores would also signal a healthier capital structure.

Watch For

Any sudden spikes in Convertible Note Risk or Warrant Exposure scores, as these may indicate upcoming dilution events.

Full SEC filing analysis available with free account  →
Track UPB Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking UPB — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for UPB
UPB FDA Catalyst Timeline & Biotech Grade — BiotechSignsUPB Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.